Cancer - New-wiki

Novel	Symbols	Name 1	Name 2	Pathways 1 Hide	Pathways 2 Hide	Drugs 1 Hide	Drugs 2 Hide	Diseases 1 Hide	Diseases 2 Hide
Novel Novel	Symbols APP and EIF4E2	Name 1 amyloid beta precursor protein	Name2 eukaryotic translation initiation factor 4E family member 2	Pathway 1 Platelet degranulation ECM proteoglycans Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs) G alpha (q) signalling events G alpha (i) signalling events Lysosome Vesicle Biogenesis Formyl peptide receptors bind formyl peptides and many other ligands TAK1-dependent IKK and NF-kappa-B activation The NLRP3 inflammasome Advanced glycosylation endproduct receptor signaling Advanced glycosylation endproduct receptor signaling Deregulated CDK5 triggers multiple neurodegenerative pathways in Alzheimer's disease models Post-translational protein phosphorylation TRAF6 mediated NF-kB activation Insertion of tail-anchored proteins into the endoplasmic reticulum membrane Insertion of tail-anchored proteins into the endoplasmic reticulum membrane Purinergic signaling in leishmaniasis infection Amyloid fiber formation	Pathway 2 ISG15 antiviral mechanism	Drugs 1 Deferoxamine Aluminium Zinc L-methionine (R)-S-oxide Resveratrol Tromethamine Phenserine Tetrathiomolybdate CAD106 Mito-4509 Edonerpic Dimercaprol Copper Florbetaben (18F) Florbetapir (18F) Flutemetamol (18F) Gantenerumab Aducanumab Zinc acetate Aluminium phosphate Aluminum acetate Zinc chloride Zinc sulfate, unspecified form Lecanemab	Drugs 2	Diseases 1 Alzheimer's disease (AD)	Diseases 2
Novel Novel	Symbols APP and RAD51AP1	Name 1 amyloid beta precursor protein	Name2 RAD51 associated protein 1	Pathway 1 Platelet degranulation ECM proteoglycans Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs) G alpha (q) signalling events G alpha (i) signalling events Lysosome Vesicle Biogenesis Formyl peptide receptors bind formyl peptides and many other ligands TAK1-dependent IKK and NF-kappa-B activation The NLRP3 inflammasome Advanced glycosylation endproduct receptor signaling Advanced glycosylation endproduct receptor signaling Deregulated CDK5 triggers multiple neurodegenerative pathways in Alzheimer's disease models Post-translational protein phosphorylation TRAF6 mediated NF-kB activation Insertion of tail-anchored proteins into the endoplasmic reticulum membrane Insertion of tail-anchored proteins into the endoplasmic reticulum membrane Purinergic signaling in leishmaniasis infection Amyloid fiber formation	Pathway 2 HDR through Homologous Recombination (HRR) Resolution of D-loop Structures through Synthesis-Dependent Strand Annealing (SDSA) Resolution of D-loop Structures through Holliday Junction Intermediates Homologous DNA Pairing and Strand Exchange Defective homologous recombination repair (HRR) due to BRCA1 loss of function Defective HDR through Homologous Recombination Repair (HRR) due to PALB2 loss of BRCA1 binding function Defective HDR through Homologous Recombination Repair (HRR) due to PALB2 loss of BRCA2/RAD51/RAD51C binding function Impaired BRCA2 binding to PALB2	Drugs 1 Deferoxamine Aluminium Zinc L-methionine (R)-S-oxide Resveratrol Tromethamine Phenserine Tetrathiomolybdate CAD106 Mito-4509 Edonerpic Dimercaprol Copper Florbetaben (18F) Florbetapir (18F) Flutemetamol (18F) Gantenerumab Aducanumab Zinc acetate Aluminium phosphate Aluminum acetate Zinc chloride Zinc sulfate, unspecified form Lecanemab	Drugs 2	Diseases 1 Alzheimer's disease (AD)	Diseases 2
Novel Novel	Symbols APP and BOD1	Name 1 amyloid beta precursor protein	Name2 biorientation of chromosomes in cell division 1	Pathway 1 Platelet degranulation ECM proteoglycans Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs) G alpha (q) signalling events G alpha (i) signalling events Lysosome Vesicle Biogenesis Formyl peptide receptors bind formyl peptides and many other ligands TAK1-dependent IKK and NF-kappa-B activation The NLRP3 inflammasome Advanced glycosylation endproduct receptor signaling Advanced glycosylation endproduct receptor signaling Deregulated CDK5 triggers multiple neurodegenerative pathways in Alzheimer's disease models Post-translational protein phosphorylation TRAF6 mediated NF-kB activation Insertion of tail-anchored proteins into the endoplasmic reticulum membrane Insertion of tail-anchored proteins into the endoplasmic reticulum membrane Purinergic signaling in leishmaniasis infection Amyloid fiber formation	Pathway 2 Formation of WDR5-containing histone-modifying complexes	Drugs 1 Deferoxamine Aluminium Zinc L-methionine (R)-S-oxide Resveratrol Tromethamine Phenserine Tetrathiomolybdate CAD106 Mito-4509 Edonerpic Dimercaprol Copper Florbetaben (18F) Florbetapir (18F) Flutemetamol (18F) Gantenerumab Aducanumab Zinc acetate Aluminium phosphate Aluminum acetate Zinc chloride Zinc sulfate, unspecified form Lecanemab	Drugs 2	Diseases 1 Alzheimer's disease (AD)	Diseases 2
Novel Novel	Symbols APP and TOX2	Name 1 amyloid beta precursor protein	Name2 TOX high mobility group box family member 2	Pathway 1 Platelet degranulation ECM proteoglycans Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs) G alpha (q) signalling events G alpha (i) signalling events Lysosome Vesicle Biogenesis Formyl peptide receptors bind formyl peptides and many other ligands TAK1-dependent IKK and NF-kappa-B activation The NLRP3 inflammasome Advanced glycosylation endproduct receptor signaling Advanced glycosylation endproduct receptor signaling Deregulated CDK5 triggers multiple neurodegenerative pathways in Alzheimer's disease models Post-translational protein phosphorylation TRAF6 mediated NF-kB activation Insertion of tail-anchored proteins into the endoplasmic reticulum membrane Insertion of tail-anchored proteins into the endoplasmic reticulum membrane Purinergic signaling in leishmaniasis infection Amyloid fiber formation	Pathway 2	Drugs 1 Deferoxamine Aluminium Zinc L-methionine (R)-S-oxide Resveratrol Tromethamine Phenserine Tetrathiomolybdate CAD106 Mito-4509 Edonerpic Dimercaprol Copper Florbetaben (18F) Florbetapir (18F) Flutemetamol (18F) Gantenerumab Aducanumab Zinc acetate Aluminium phosphate Aluminum acetate Zinc chloride Zinc sulfate, unspecified form Lecanemab	Drugs 2	Diseases 1 Alzheimer's disease (AD)	Diseases 2
Novel Novel	Symbols APP and IRS1	Name 1 amyloid beta precursor protein	Name2 insulin receptor substrate 1	Pathway 1 Platelet degranulation ECM proteoglycans Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs) G alpha (q) signalling events G alpha (i) signalling events Lysosome Vesicle Biogenesis Formyl peptide receptors bind formyl peptides and many other ligands TAK1-dependent IKK and NF-kappa-B activation The NLRP3 inflammasome Advanced glycosylation endproduct receptor signaling Advanced glycosylation endproduct receptor signaling Deregulated CDK5 triggers multiple neurodegenerative pathways in Alzheimer's disease models Post-translational protein phosphorylation TRAF6 mediated NF-kB activation Insertion of tail-anchored proteins into the endoplasmic reticulum membrane Insertion of tail-anchored proteins into the endoplasmic reticulum membrane Purinergic signaling in leishmaniasis infection Amyloid fiber formation	Pathway 2 PI3K Cascade IRS-mediated signalling SOS-mediated signalling SOS-mediated signalling PIP3 activates AKT signaling Interleukin-7 signaling PI3K/AKT activation PI3K/AKT activation Signaling by ALK Constitutive Signaling by Aberrant PI3K in Cancer IRS-related events triggered by IGF1R Signaling by Leptin RAF/MAP kinase cascade PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling IRS activation Signal attenuation Activated NTRK3 signals through PI3K Signaling by ALK fusions and activated point mutants Growth hormone receptor signaling Signaling by LTK	Drugs 1 Deferoxamine Aluminium Zinc L-methionine (R)-S-oxide Resveratrol Tromethamine Phenserine Tetrathiomolybdate CAD106 Mito-4509 Edonerpic Dimercaprol Copper Florbetaben (18F) Florbetapir (18F) Flutemetamol (18F) Gantenerumab Aducanumab Zinc acetate Aluminium phosphate Aluminum acetate Zinc chloride Zinc sulfate, unspecified form Lecanemab	Drugs 2 [4-({5-(AMINOCARBONYL)-4-[(3-METHYLPHENYL)AMINO]PYRIMIDIN-2-YL}AMINO)PHENYL]ACETIC ACID	Diseases 1 Alzheimer's disease (AD)	Diseases 2
Novel Novel	Symbols APP and FEN1	Name 1 amyloid beta precursor protein	Name2 flap structure-specific endonuclease 1	Pathway 1 Platelet degranulation ECM proteoglycans Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs) G alpha (q) signalling events G alpha (i) signalling events Lysosome Vesicle Biogenesis Formyl peptide receptors bind formyl peptides and many other ligands TAK1-dependent IKK and NF-kappa-B activation The NLRP3 inflammasome Advanced glycosylation endproduct receptor signaling Advanced glycosylation endproduct receptor signaling Deregulated CDK5 triggers multiple neurodegenerative pathways in Alzheimer's disease models Post-translational protein phosphorylation TRAF6 mediated NF-kB activation Insertion of tail-anchored proteins into the endoplasmic reticulum membrane Insertion of tail-anchored proteins into the endoplasmic reticulum membrane Purinergic signaling in leishmaniasis infection Amyloid fiber formation	Pathway 2 POLB-Dependent Long Patch Base Excision Repair Early Phase of HIV Life Cycle Removal of the Flap Intermediate from the C-strand PCNA-Dependent Long Patch Base Excision Repair HDR through MMEJ (alt-NHEJ) Removal of the Flap Intermediate	Drugs 1 Deferoxamine Aluminium Zinc L-methionine (R)-S-oxide Resveratrol Tromethamine Phenserine Tetrathiomolybdate CAD106 Mito-4509 Edonerpic Dimercaprol Copper Florbetaben (18F) Florbetapir (18F) Flutemetamol (18F) Gantenerumab Aducanumab Zinc acetate Aluminium phosphate Aluminum acetate Zinc chloride Zinc sulfate, unspecified form Lecanemab	Drugs 2 Iron Ferrous gluconate Ferrous succinate Ferrous ascorbate Ferrous fumarate Ferrous glycine sulfate	Diseases 1 Alzheimer's disease (AD)	Diseases 2
Novel Novel	Symbols APP and ARGLU1	Name 1 amyloid beta precursor protein	Name2 arginine and glutamate rich 1	Pathway 1 Platelet degranulation ECM proteoglycans Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs) G alpha (q) signalling events G alpha (i) signalling events Lysosome Vesicle Biogenesis Formyl peptide receptors bind formyl peptides and many other ligands TAK1-dependent IKK and NF-kappa-B activation The NLRP3 inflammasome Advanced glycosylation endproduct receptor signaling Advanced glycosylation endproduct receptor signaling Deregulated CDK5 triggers multiple neurodegenerative pathways in Alzheimer's disease models Post-translational protein phosphorylation TRAF6 mediated NF-kB activation Insertion of tail-anchored proteins into the endoplasmic reticulum membrane Insertion of tail-anchored proteins into the endoplasmic reticulum membrane Purinergic signaling in leishmaniasis infection Amyloid fiber formation	Pathway 2	Drugs 1 Deferoxamine Aluminium Zinc L-methionine (R)-S-oxide Resveratrol Tromethamine Phenserine Tetrathiomolybdate CAD106 Mito-4509 Edonerpic Dimercaprol Copper Florbetaben (18F) Florbetapir (18F) Flutemetamol (18F) Gantenerumab Aducanumab Zinc acetate Aluminium phosphate Aluminum acetate Zinc chloride Zinc sulfate, unspecified form Lecanemab	Drugs 2	Diseases 1 Alzheimer's disease (AD)	Diseases 2
Novel Novel	Symbols APP and POLD3	Name 1 amyloid beta precursor protein	Name2 DNA polymerase delta 3, accessory subunit	Pathway 1 Platelet degranulation ECM proteoglycans Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs) G alpha (q) signalling events G alpha (i) signalling events Lysosome Vesicle Biogenesis Formyl peptide receptors bind formyl peptides and many other ligands TAK1-dependent IKK and NF-kappa-B activation The NLRP3 inflammasome Advanced glycosylation endproduct receptor signaling Advanced glycosylation endproduct receptor signaling Deregulated CDK5 triggers multiple neurodegenerative pathways in Alzheimer's disease models Post-translational protein phosphorylation TRAF6 mediated NF-kB activation Insertion of tail-anchored proteins into the endoplasmic reticulum membrane Insertion of tail-anchored proteins into the endoplasmic reticulum membrane Purinergic signaling in leishmaniasis infection Amyloid fiber formation	Pathway 2 Recognition of DNA damage by PCNA-containing replication complex Polymerase switching on the C-strand of the telomere Processive synthesis on the C-strand of the telomere Telomere C-strand (Lagging Strand) Synthesis Removal of the Flap Intermediate from the C-strand Mismatch repair (MMR) directed by MSH2:MSH6 (MutSalpha) Mismatch repair (MMR) directed by MSH2:MSH3 (MutSbeta) PCNA-Dependent Long Patch Base Excision Repair Termination of translesion DNA synthesis HDR through Homologous Recombination (HRR) Gap-filling DNA repair synthesis and ligation in GG-NER Dual Incision in GG-NER Dual incision in TC-NER Gap-filling DNA repair synthesis and ligation in TC-NER Polymerase switching Removal of the Flap Intermediate Processive synthesis on the lagging strand	Drugs 1 Deferoxamine Aluminium Zinc L-methionine (R)-S-oxide Resveratrol Tromethamine Phenserine Tetrathiomolybdate CAD106 Mito-4509 Edonerpic Dimercaprol Copper Florbetaben (18F) Florbetapir (18F) Flutemetamol (18F) Gantenerumab Aducanumab Zinc acetate Aluminium phosphate Aluminum acetate Zinc chloride Zinc sulfate, unspecified form Lecanemab	Drugs 2	Diseases 1 Alzheimer's disease (AD)	Diseases 2
Novel Novel	Symbols APP and PLIN3	Name 1 amyloid beta precursor protein	Name2 perilipin 3	Pathway 1 Platelet degranulation ECM proteoglycans Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs) G alpha (q) signalling events G alpha (i) signalling events Lysosome Vesicle Biogenesis Formyl peptide receptors bind formyl peptides and many other ligands TAK1-dependent IKK and NF-kappa-B activation The NLRP3 inflammasome Advanced glycosylation endproduct receptor signaling Advanced glycosylation endproduct receptor signaling Deregulated CDK5 triggers multiple neurodegenerative pathways in Alzheimer's disease models Post-translational protein phosphorylation TRAF6 mediated NF-kB activation Insertion of tail-anchored proteins into the endoplasmic reticulum membrane Insertion of tail-anchored proteins into the endoplasmic reticulum membrane Purinergic signaling in leishmaniasis infection Amyloid fiber formation	Pathway 2 Triglyceride catabolism Retrograde transport at the Trans-Golgi-Network Lipophagy Chaperone Mediated Autophagy Late endosomal microautophagy RHOBTB3 ATPase cycle	Drugs 1 Deferoxamine Aluminium Zinc L-methionine (R)-S-oxide Resveratrol Tromethamine Phenserine Tetrathiomolybdate CAD106 Mito-4509 Edonerpic Dimercaprol Copper Florbetaben (18F) Florbetapir (18F) Flutemetamol (18F) Gantenerumab Aducanumab Zinc acetate Aluminium phosphate Aluminum acetate Zinc chloride Zinc sulfate, unspecified form Lecanemab	Drugs 2 Idursulfase Galsulfase	Diseases 1 Alzheimer's disease (AD)	Diseases 2
Novel Novel	Symbols APP and TAF1B	Name 1 amyloid beta precursor protein	Name2 TATA-box binding protein associated factor, RNA polymerase I subunit B	Pathway 1 Platelet degranulation ECM proteoglycans Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs) G alpha (q) signalling events G alpha (i) signalling events Lysosome Vesicle Biogenesis Formyl peptide receptors bind formyl peptides and many other ligands TAK1-dependent IKK and NF-kappa-B activation The NLRP3 inflammasome Advanced glycosylation endproduct receptor signaling Advanced glycosylation endproduct receptor signaling Deregulated CDK5 triggers multiple neurodegenerative pathways in Alzheimer's disease models Post-translational protein phosphorylation TRAF6 mediated NF-kB activation Insertion of tail-anchored proteins into the endoplasmic reticulum membrane Insertion of tail-anchored proteins into the endoplasmic reticulum membrane Purinergic signaling in leishmaniasis infection Amyloid fiber formation	Pathway 2 SIRT1 negatively regulates rRNA expression NoRC negatively regulates rRNA expression B-WICH complex positively regulates rRNA expression RNA Polymerase I Transcription Initiation RNA Polymerase I Transcription Initiation RNA Polymerase I Promoter Escape RNA Polymerase I Transcription Termination	Drugs 1 Deferoxamine Aluminium Zinc L-methionine (R)-S-oxide Resveratrol Tromethamine Phenserine Tetrathiomolybdate CAD106 Mito-4509 Edonerpic Dimercaprol Copper Florbetaben (18F) Florbetapir (18F) Flutemetamol (18F) Gantenerumab Aducanumab Zinc acetate Aluminium phosphate Aluminum acetate Zinc chloride Zinc sulfate, unspecified form Lecanemab	Drugs 2	Diseases 1 Alzheimer's disease (AD)	Diseases 2
Novel Novel	Symbols APP and ARL4C	Name 1 amyloid beta precursor protein	Name2 ARF like GTPase 4C	Pathway 1 Platelet degranulation ECM proteoglycans Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs) G alpha (q) signalling events G alpha (i) signalling events Lysosome Vesicle Biogenesis Formyl peptide receptors bind formyl peptides and many other ligands TAK1-dependent IKK and NF-kappa-B activation The NLRP3 inflammasome Advanced glycosylation endproduct receptor signaling Advanced glycosylation endproduct receptor signaling Deregulated CDK5 triggers multiple neurodegenerative pathways in Alzheimer's disease models Post-translational protein phosphorylation TRAF6 mediated NF-kB activation Insertion of tail-anchored proteins into the endoplasmic reticulum membrane Insertion of tail-anchored proteins into the endoplasmic reticulum membrane Purinergic signaling in leishmaniasis infection Amyloid fiber formation	Pathway 2 NR1H3 & NR1H2 regulate gene expression linked to cholesterol transport and efflux	Drugs 1 Deferoxamine Aluminium Zinc L-methionine (R)-S-oxide Resveratrol Tromethamine Phenserine Tetrathiomolybdate CAD106 Mito-4509 Edonerpic Dimercaprol Copper Florbetaben (18F) Florbetapir (18F) Flutemetamol (18F) Gantenerumab Aducanumab Zinc acetate Aluminium phosphate Aluminum acetate Zinc chloride Zinc sulfate, unspecified form Lecanemab	Drugs 2	Diseases 1 Alzheimer's disease (AD)	Diseases 2
Novel Novel	Symbols APP and ZAP70	Name 1 amyloid beta precursor protein	Name2 zeta chain of T cell receptor associated protein kinase 70	Pathway 1 Platelet degranulation ECM proteoglycans Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs) G alpha (q) signalling events G alpha (i) signalling events Lysosome Vesicle Biogenesis Formyl peptide receptors bind formyl peptides and many other ligands TAK1-dependent IKK and NF-kappa-B activation The NLRP3 inflammasome Advanced glycosylation endproduct receptor signaling Advanced glycosylation endproduct receptor signaling Deregulated CDK5 triggers multiple neurodegenerative pathways in Alzheimer's disease models Post-translational protein phosphorylation TRAF6 mediated NF-kB activation Insertion of tail-anchored proteins into the endoplasmic reticulum membrane Insertion of tail-anchored proteins into the endoplasmic reticulum membrane Purinergic signaling in leishmaniasis infection Amyloid fiber formation	Pathway 2 Translocation of ZAP-70 to Immunological synapse Generation of second messenger molecules RHOH GTPase cycle Nuclear events stimulated by ALK signaling in cancer	Drugs 1 Deferoxamine Aluminium Zinc L-methionine (R)-S-oxide Resveratrol Tromethamine Phenserine Tetrathiomolybdate CAD106 Mito-4509 Edonerpic Dimercaprol Copper Florbetaben (18F) Florbetapir (18F) Flutemetamol (18F) Gantenerumab Aducanumab Zinc acetate Aluminium phosphate Aluminum acetate Zinc chloride Zinc sulfate, unspecified form Lecanemab	Drugs 2 Staurosporine Fostamatinib	Diseases 1 Alzheimer's disease (AD)	Diseases 2 Combined immunodeficiencies (CIDs), including the following nine diseases: X-linked hyper IgM syndrome; CD40 deficiency hyper IgM syndrome; Purine nucleoside phosphorylase (PNP) deficiency; Omenn syndrome; MHC deficiency (HLA-class I); MHC deficiency (HLA-class II); Zap-70 deficiency; p56 Lck deficiency; CD8 deficiency
Novel Novel	Symbols APP and ATAT1	Name 1 amyloid beta precursor protein	Name2 alpha tubulin acetyltransferase 1	Pathway 1 Platelet degranulation ECM proteoglycans Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs) G alpha (q) signalling events G alpha (i) signalling events Lysosome Vesicle Biogenesis Formyl peptide receptors bind formyl peptides and many other ligands TAK1-dependent IKK and NF-kappa-B activation The NLRP3 inflammasome Advanced glycosylation endproduct receptor signaling Advanced glycosylation endproduct receptor signaling Deregulated CDK5 triggers multiple neurodegenerative pathways in Alzheimer's disease models Post-translational protein phosphorylation TRAF6 mediated NF-kB activation Insertion of tail-anchored proteins into the endoplasmic reticulum membrane Insertion of tail-anchored proteins into the endoplasmic reticulum membrane Purinergic signaling in leishmaniasis infection Amyloid fiber formation	Pathway 2 Cargo trafficking to the periciliary membrane	Drugs 1 Deferoxamine Aluminium Zinc L-methionine (R)-S-oxide Resveratrol Tromethamine Phenserine Tetrathiomolybdate CAD106 Mito-4509 Edonerpic Dimercaprol Copper Florbetaben (18F) Florbetapir (18F) Flutemetamol (18F) Gantenerumab Aducanumab Zinc acetate Aluminium phosphate Aluminum acetate Zinc chloride Zinc sulfate, unspecified form Lecanemab	Drugs 2	Diseases 1 Alzheimer's disease (AD)	Diseases 2
Novel Novel	Symbols APP and STK25	Name 1 amyloid beta precursor protein	Name2 serine/threonine kinase 25	Pathway 1 Platelet degranulation ECM proteoglycans Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs) G alpha (q) signalling events G alpha (i) signalling events Lysosome Vesicle Biogenesis Formyl peptide receptors bind formyl peptides and many other ligands TAK1-dependent IKK and NF-kappa-B activation The NLRP3 inflammasome Advanced glycosylation endproduct receptor signaling Advanced glycosylation endproduct receptor signaling Deregulated CDK5 triggers multiple neurodegenerative pathways in Alzheimer's disease models Post-translational protein phosphorylation TRAF6 mediated NF-kB activation Insertion of tail-anchored proteins into the endoplasmic reticulum membrane Insertion of tail-anchored proteins into the endoplasmic reticulum membrane Purinergic signaling in leishmaniasis infection Amyloid fiber formation	Pathway 2	Drugs 1 Deferoxamine Aluminium Zinc L-methionine (R)-S-oxide Resveratrol Tromethamine Phenserine Tetrathiomolybdate CAD106 Mito-4509 Edonerpic Dimercaprol Copper Florbetaben (18F) Florbetapir (18F) Flutemetamol (18F) Gantenerumab Aducanumab Zinc acetate Aluminium phosphate Aluminum acetate Zinc chloride Zinc sulfate, unspecified form Lecanemab	Drugs 2	Diseases 1 Alzheimer's disease (AD)	Diseases 2
Novel Novel	Symbols APP and PTPN7	Name 1 amyloid beta precursor protein	Name2 protein tyrosine phosphatase non-receptor type 7	Pathway 1 Platelet degranulation ECM proteoglycans Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs) G alpha (q) signalling events G alpha (i) signalling events Lysosome Vesicle Biogenesis Formyl peptide receptors bind formyl peptides and many other ligands TAK1-dependent IKK and NF-kappa-B activation The NLRP3 inflammasome Advanced glycosylation endproduct receptor signaling Advanced glycosylation endproduct receptor signaling Deregulated CDK5 triggers multiple neurodegenerative pathways in Alzheimer's disease models Post-translational protein phosphorylation TRAF6 mediated NF-kB activation Insertion of tail-anchored proteins into the endoplasmic reticulum membrane Insertion of tail-anchored proteins into the endoplasmic reticulum membrane Purinergic signaling in leishmaniasis infection Amyloid fiber formation	Pathway 2 Negative regulation of MAPK pathway Interleukin-37 signaling	Drugs 1 Deferoxamine Aluminium Zinc L-methionine (R)-S-oxide Resveratrol Tromethamine Phenserine Tetrathiomolybdate CAD106 Mito-4509 Edonerpic Dimercaprol Copper Florbetaben (18F) Florbetapir (18F) Flutemetamol (18F) Gantenerumab Aducanumab Zinc acetate Aluminium phosphate Aluminum acetate Zinc chloride Zinc sulfate, unspecified form Lecanemab	Drugs 2	Diseases 1 Alzheimer's disease (AD)	Diseases 2
Novel Novel	Symbols APP and EPB41L2	Name 1 amyloid beta precursor protein	Name2 erythrocyte membrane protein band 4.1 like 2	Pathway 1 Platelet degranulation ECM proteoglycans Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs) G alpha (q) signalling events G alpha (i) signalling events Lysosome Vesicle Biogenesis Formyl peptide receptors bind formyl peptides and many other ligands TAK1-dependent IKK and NF-kappa-B activation The NLRP3 inflammasome Advanced glycosylation endproduct receptor signaling Advanced glycosylation endproduct receptor signaling Deregulated CDK5 triggers multiple neurodegenerative pathways in Alzheimer's disease models Post-translational protein phosphorylation TRAF6 mediated NF-kB activation Insertion of tail-anchored proteins into the endoplasmic reticulum membrane Insertion of tail-anchored proteins into the endoplasmic reticulum membrane Purinergic signaling in leishmaniasis infection Amyloid fiber formation	Pathway 2 Neurexins and neuroligins	Drugs 1 Deferoxamine Aluminium Zinc L-methionine (R)-S-oxide Resveratrol Tromethamine Phenserine Tetrathiomolybdate CAD106 Mito-4509 Edonerpic Dimercaprol Copper Florbetaben (18F) Florbetapir (18F) Flutemetamol (18F) Gantenerumab Aducanumab Zinc acetate Aluminium phosphate Aluminum acetate Zinc chloride Zinc sulfate, unspecified form Lecanemab	Drugs 2	Diseases 1 Alzheimer's disease (AD)	Diseases 2
Novel Novel	Symbols APP and LIG3	Name 1 amyloid beta precursor protein	Name2 DNA ligase 3	Pathway 1 Platelet degranulation ECM proteoglycans Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs) G alpha (q) signalling events G alpha (i) signalling events Lysosome Vesicle Biogenesis Formyl peptide receptors bind formyl peptides and many other ligands TAK1-dependent IKK and NF-kappa-B activation The NLRP3 inflammasome Advanced glycosylation endproduct receptor signaling Advanced glycosylation endproduct receptor signaling Deregulated CDK5 triggers multiple neurodegenerative pathways in Alzheimer's disease models Post-translational protein phosphorylation TRAF6 mediated NF-kB activation Insertion of tail-anchored proteins into the endoplasmic reticulum membrane Insertion of tail-anchored proteins into the endoplasmic reticulum membrane Purinergic signaling in leishmaniasis infection Amyloid fiber formation	Pathway 2 Resolution of AP sites via the single-nucleotide replacement pathway APEX1-Independent Resolution of AP Sites via the Single Nucleotide Replacement Pathway HDR through MMEJ (alt-NHEJ) Gap-filling DNA repair synthesis and ligation in GG-NER Gap-filling DNA repair synthesis and ligation in TC-NER	Drugs 1 Deferoxamine Aluminium Zinc L-methionine (R)-S-oxide Resveratrol Tromethamine Phenserine Tetrathiomolybdate CAD106 Mito-4509 Edonerpic Dimercaprol Copper Florbetaben (18F) Florbetapir (18F) Flutemetamol (18F) Gantenerumab Aducanumab Zinc acetate Aluminium phosphate Aluminum acetate Zinc chloride Zinc sulfate, unspecified form Lecanemab	Drugs 2 Bleomycin	Diseases 1 Alzheimer's disease (AD)	Diseases 2
Novel Novel	Symbols APP and PPFIBP2	Name 1 amyloid beta precursor protein	Name2 PPFIB scaffold protein 2	Pathway 1 Platelet degranulation ECM proteoglycans Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs) G alpha (q) signalling events G alpha (i) signalling events Lysosome Vesicle Biogenesis Formyl peptide receptors bind formyl peptides and many other ligands TAK1-dependent IKK and NF-kappa-B activation The NLRP3 inflammasome Advanced glycosylation endproduct receptor signaling Advanced glycosylation endproduct receptor signaling Deregulated CDK5 triggers multiple neurodegenerative pathways in Alzheimer's disease models Post-translational protein phosphorylation TRAF6 mediated NF-kB activation Insertion of tail-anchored proteins into the endoplasmic reticulum membrane Insertion of tail-anchored proteins into the endoplasmic reticulum membrane Purinergic signaling in leishmaniasis infection Amyloid fiber formation	Pathway 2 Receptor-type tyrosine-protein phosphatases	Drugs 1 Deferoxamine Aluminium Zinc L-methionine (R)-S-oxide Resveratrol Tromethamine Phenserine Tetrathiomolybdate CAD106 Mito-4509 Edonerpic Dimercaprol Copper Florbetaben (18F) Florbetapir (18F) Flutemetamol (18F) Gantenerumab Aducanumab Zinc acetate Aluminium phosphate Aluminum acetate Zinc chloride Zinc sulfate, unspecified form Lecanemab	Drugs 2	Diseases 1 Alzheimer's disease (AD)	Diseases 2
Novel Novel	Symbols APP and TAB2	Name 1 amyloid beta precursor protein	Name2 TGF-beta activated kinase 1 (MAP3K7) binding protein 2	Pathway 1 Platelet degranulation ECM proteoglycans Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs) G alpha (q) signalling events G alpha (i) signalling events Lysosome Vesicle Biogenesis Formyl peptide receptors bind formyl peptides and many other ligands TAK1-dependent IKK and NF-kappa-B activation The NLRP3 inflammasome Advanced glycosylation endproduct receptor signaling Advanced glycosylation endproduct receptor signaling Deregulated CDK5 triggers multiple neurodegenerative pathways in Alzheimer's disease models Post-translational protein phosphorylation TRAF6 mediated NF-kB activation Insertion of tail-anchored proteins into the endoplasmic reticulum membrane Insertion of tail-anchored proteins into the endoplasmic reticulum membrane Purinergic signaling in leishmaniasis infection Amyloid fiber formation	Pathway 2 Nuclear signaling by ERBB4 Nuclear signaling by ERBB4 NOD1/2 Signaling Pathway Downstream TCR signaling FCERI mediated NF-kB activation TAK1-dependent IKK and NF-kappa-B activation activated TAK1 mediates p38 MAPK activation JNK (c-Jun kinases) phosphorylation and activation mediated by activated human TAK1 TNFR1-induced NF-kappa-B signaling pathway CLEC7A (Dectin-1) signaling TICAM1,TRAF6-dependent induction of TAK1 complex Interleukin-1 signaling IRAK2 mediated activation of TAK1 complex TRAF6-mediated induction of TAK1 complex within TLR4 complex Alpha-protein kinase 1 signaling pathway SARS-CoV-2 activates/modulates innate and adaptive immune responses IRAK2 mediated activation of TAK1 complex upon TLR7/8 or 9 stimulation	Drugs 1 Deferoxamine Aluminium Zinc L-methionine (R)-S-oxide Resveratrol Tromethamine Phenserine Tetrathiomolybdate CAD106 Mito-4509 Edonerpic Dimercaprol Copper Florbetaben (18F) Florbetapir (18F) Flutemetamol (18F) Gantenerumab Aducanumab Zinc acetate Aluminium phosphate Aluminum acetate Zinc chloride Zinc sulfate, unspecified form Lecanemab	Drugs 2	Diseases 1 Alzheimer's disease (AD)	Diseases 2
Novel Novel	Symbols APP and LRRC8D	Name 1 amyloid beta precursor protein	Name2 leucine rich repeat containing 8 VRAC subunit D	Pathway 1 Platelet degranulation ECM proteoglycans Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs) G alpha (q) signalling events G alpha (i) signalling events Lysosome Vesicle Biogenesis Formyl peptide receptors bind formyl peptides and many other ligands TAK1-dependent IKK and NF-kappa-B activation The NLRP3 inflammasome Advanced glycosylation endproduct receptor signaling Advanced glycosylation endproduct receptor signaling Deregulated CDK5 triggers multiple neurodegenerative pathways in Alzheimer's disease models Post-translational protein phosphorylation TRAF6 mediated NF-kB activation Insertion of tail-anchored proteins into the endoplasmic reticulum membrane Insertion of tail-anchored proteins into the endoplasmic reticulum membrane Purinergic signaling in leishmaniasis infection Amyloid fiber formation	Pathway 2 Miscellaneous transport and binding events	Drugs 1 Deferoxamine Aluminium Zinc L-methionine (R)-S-oxide Resveratrol Tromethamine Phenserine Tetrathiomolybdate CAD106 Mito-4509 Edonerpic Dimercaprol Copper Florbetaben (18F) Florbetapir (18F) Flutemetamol (18F) Gantenerumab Aducanumab Zinc acetate Aluminium phosphate Aluminum acetate Zinc chloride Zinc sulfate, unspecified form Lecanemab	Drugs 2	Diseases 1 Alzheimer's disease (AD)	Diseases 2 Agammaglobulinemias, including the following six diseases: X-linked agammaglobulinemia (Bruton's agammaglobulinemia, XLA); IgM heavy chain gene deletions; Ig-alpha defect; Autosomal recessive agammaglobulinaemia; B cell-linker protein (BLNK) deficiency; Leucine-rich repeat-containing 8
Novel	Symbols APP and EIF4E2	Name 1 amyloid beta precursor protein	Name2 eukaryotic translation initiation factor 4E family member 2	Pathway 1 Platelet degranulation ECM proteoglycans Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs) G alpha (q) signalling events G alpha (i) signalling events Lysosome Vesicle Biogenesis Formyl peptide receptors bind formyl peptides and many other ligands TAK1-dependent IKK and NF-kappa-B activation The NLRP3 inflammasome Advanced glycosylation endproduct receptor signaling Advanced glycosylation endproduct receptor signaling Deregulated CDK5 triggers multiple neurodegenerative pathways in Alzheimer's disease models Post-translational protein phosphorylation TRAF6 mediated NF-kB activation Insertion of tail-anchored proteins into the endoplasmic reticulum membrane Insertion of tail-anchored proteins into the endoplasmic reticulum membrane Purinergic signaling in leishmaniasis infection Amyloid fiber formation	Pathway 2 ISG15 antiviral mechanism	Drugs 1 Deferoxamine Aluminium Zinc L-methionine (R)-S-oxide Resveratrol Tromethamine Phenserine Tetrathiomolybdate CAD106 Mito-4509 Edonerpic Dimercaprol Copper Florbetaben (18F) Florbetapir (18F) Flutemetamol (18F) Gantenerumab Aducanumab Zinc acetate Aluminium phosphate Aluminum acetate Zinc chloride Zinc sulfate, unspecified form Lecanemab	Drugs 2	Diseases 1 Alzheimer's disease (AD)	Diseases 2
Novel	Symbols APP and RAD51AP1	Name 1 amyloid beta precursor protein	Name2 RAD51 associated protein 1	Pathway 1 Platelet degranulation ECM proteoglycans Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs) G alpha (q) signalling events G alpha (i) signalling events Lysosome Vesicle Biogenesis Formyl peptide receptors bind formyl peptides and many other ligands TAK1-dependent IKK and NF-kappa-B activation The NLRP3 inflammasome Advanced glycosylation endproduct receptor signaling Advanced glycosylation endproduct receptor signaling Deregulated CDK5 triggers multiple neurodegenerative pathways in Alzheimer's disease models Post-translational protein phosphorylation TRAF6 mediated NF-kB activation Insertion of tail-anchored proteins into the endoplasmic reticulum membrane Insertion of tail-anchored proteins into the endoplasmic reticulum membrane Purinergic signaling in leishmaniasis infection Amyloid fiber formation	Pathway 2 HDR through Homologous Recombination (HRR) Resolution of D-loop Structures through Synthesis-Dependent Strand Annealing (SDSA) Resolution of D-loop Structures through Holliday Junction Intermediates Homologous DNA Pairing and Strand Exchange Defective homologous recombination repair (HRR) due to BRCA1 loss of function Defective HDR through Homologous Recombination Repair (HRR) due to PALB2 loss of BRCA1 binding function Defective HDR through Homologous Recombination Repair (HRR) due to PALB2 loss of BRCA2/RAD51/RAD51C binding function Impaired BRCA2 binding to PALB2	Drugs 1 Deferoxamine Aluminium Zinc L-methionine (R)-S-oxide Resveratrol Tromethamine Phenserine Tetrathiomolybdate CAD106 Mito-4509 Edonerpic Dimercaprol Copper Florbetaben (18F) Florbetapir (18F) Flutemetamol (18F) Gantenerumab Aducanumab Zinc acetate Aluminium phosphate Aluminum acetate Zinc chloride Zinc sulfate, unspecified form Lecanemab	Drugs 2	Diseases 1 Alzheimer's disease (AD)	Diseases 2
Novel	Symbols APP and BOD1	Name 1 amyloid beta precursor protein	Name2 biorientation of chromosomes in cell division 1	Pathway 1 Platelet degranulation ECM proteoglycans Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs) G alpha (q) signalling events G alpha (i) signalling events Lysosome Vesicle Biogenesis Formyl peptide receptors bind formyl peptides and many other ligands TAK1-dependent IKK and NF-kappa-B activation The NLRP3 inflammasome Advanced glycosylation endproduct receptor signaling Advanced glycosylation endproduct receptor signaling Deregulated CDK5 triggers multiple neurodegenerative pathways in Alzheimer's disease models Post-translational protein phosphorylation TRAF6 mediated NF-kB activation Insertion of tail-anchored proteins into the endoplasmic reticulum membrane Insertion of tail-anchored proteins into the endoplasmic reticulum membrane Purinergic signaling in leishmaniasis infection Amyloid fiber formation	Pathway 2 Formation of WDR5-containing histone-modifying complexes	Drugs 1 Deferoxamine Aluminium Zinc L-methionine (R)-S-oxide Resveratrol Tromethamine Phenserine Tetrathiomolybdate CAD106 Mito-4509 Edonerpic Dimercaprol Copper Florbetaben (18F) Florbetapir (18F) Flutemetamol (18F) Gantenerumab Aducanumab Zinc acetate Aluminium phosphate Aluminum acetate Zinc chloride Zinc sulfate, unspecified form Lecanemab	Drugs 2	Diseases 1 Alzheimer's disease (AD)	Diseases 2
Novel	Symbols APP and TOX2	Name 1 amyloid beta precursor protein	Name2 TOX high mobility group box family member 2	Pathway 1 Platelet degranulation ECM proteoglycans Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs) G alpha (q) signalling events G alpha (i) signalling events Lysosome Vesicle Biogenesis Formyl peptide receptors bind formyl peptides and many other ligands TAK1-dependent IKK and NF-kappa-B activation The NLRP3 inflammasome Advanced glycosylation endproduct receptor signaling Advanced glycosylation endproduct receptor signaling Deregulated CDK5 triggers multiple neurodegenerative pathways in Alzheimer's disease models Post-translational protein phosphorylation TRAF6 mediated NF-kB activation Insertion of tail-anchored proteins into the endoplasmic reticulum membrane Insertion of tail-anchored proteins into the endoplasmic reticulum membrane Purinergic signaling in leishmaniasis infection Amyloid fiber formation	Pathway 2	Drugs 1 Deferoxamine Aluminium Zinc L-methionine (R)-S-oxide Resveratrol Tromethamine Phenserine Tetrathiomolybdate CAD106 Mito-4509 Edonerpic Dimercaprol Copper Florbetaben (18F) Florbetapir (18F) Flutemetamol (18F) Gantenerumab Aducanumab Zinc acetate Aluminium phosphate Aluminum acetate Zinc chloride Zinc sulfate, unspecified form Lecanemab	Drugs 2	Diseases 1 Alzheimer's disease (AD)	Diseases 2
Novel	Symbols APP and IRS1	Name 1 amyloid beta precursor protein	Name2 insulin receptor substrate 1	Pathway 1 Platelet degranulation ECM proteoglycans Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs) G alpha (q) signalling events G alpha (i) signalling events Lysosome Vesicle Biogenesis Formyl peptide receptors bind formyl peptides and many other ligands TAK1-dependent IKK and NF-kappa-B activation The NLRP3 inflammasome Advanced glycosylation endproduct receptor signaling Advanced glycosylation endproduct receptor signaling Deregulated CDK5 triggers multiple neurodegenerative pathways in Alzheimer's disease models Post-translational protein phosphorylation TRAF6 mediated NF-kB activation Insertion of tail-anchored proteins into the endoplasmic reticulum membrane Insertion of tail-anchored proteins into the endoplasmic reticulum membrane Purinergic signaling in leishmaniasis infection Amyloid fiber formation	Pathway 2 PI3K Cascade IRS-mediated signalling SOS-mediated signalling SOS-mediated signalling PIP3 activates AKT signaling Interleukin-7 signaling PI3K/AKT activation PI3K/AKT activation Signaling by ALK Constitutive Signaling by Aberrant PI3K in Cancer IRS-related events triggered by IGF1R Signaling by Leptin RAF/MAP kinase cascade PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling IRS activation Signal attenuation Activated NTRK3 signals through PI3K Signaling by ALK fusions and activated point mutants Growth hormone receptor signaling Signaling by LTK	Drugs 1 Deferoxamine Aluminium Zinc L-methionine (R)-S-oxide Resveratrol Tromethamine Phenserine Tetrathiomolybdate CAD106 Mito-4509 Edonerpic Dimercaprol Copper Florbetaben (18F) Florbetapir (18F) Flutemetamol (18F) Gantenerumab Aducanumab Zinc acetate Aluminium phosphate Aluminum acetate Zinc chloride Zinc sulfate, unspecified form Lecanemab	Drugs 2 [4-({5-(AMINOCARBONYL)-4-[(3-METHYLPHENYL)AMINO]PYRIMIDIN-2-YL}AMINO)PHENYL]ACETIC ACID	Diseases 1 Alzheimer's disease (AD)	Diseases 2
Novel	Symbols APP and FEN1	Name 1 amyloid beta precursor protein	Name2 flap structure-specific endonuclease 1	Pathway 1 Platelet degranulation ECM proteoglycans Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs) G alpha (q) signalling events G alpha (i) signalling events Lysosome Vesicle Biogenesis Formyl peptide receptors bind formyl peptides and many other ligands TAK1-dependent IKK and NF-kappa-B activation The NLRP3 inflammasome Advanced glycosylation endproduct receptor signaling Advanced glycosylation endproduct receptor signaling Deregulated CDK5 triggers multiple neurodegenerative pathways in Alzheimer's disease models Post-translational protein phosphorylation TRAF6 mediated NF-kB activation Insertion of tail-anchored proteins into the endoplasmic reticulum membrane Insertion of tail-anchored proteins into the endoplasmic reticulum membrane Purinergic signaling in leishmaniasis infection Amyloid fiber formation	Pathway 2 POLB-Dependent Long Patch Base Excision Repair Early Phase of HIV Life Cycle Removal of the Flap Intermediate from the C-strand PCNA-Dependent Long Patch Base Excision Repair HDR through MMEJ (alt-NHEJ) Removal of the Flap Intermediate	Drugs 1 Deferoxamine Aluminium Zinc L-methionine (R)-S-oxide Resveratrol Tromethamine Phenserine Tetrathiomolybdate CAD106 Mito-4509 Edonerpic Dimercaprol Copper Florbetaben (18F) Florbetapir (18F) Flutemetamol (18F) Gantenerumab Aducanumab Zinc acetate Aluminium phosphate Aluminum acetate Zinc chloride Zinc sulfate, unspecified form Lecanemab	Drugs 2 Iron Ferrous gluconate Ferrous succinate Ferrous ascorbate Ferrous fumarate Ferrous glycine sulfate	Diseases 1 Alzheimer's disease (AD)	Diseases 2
Novel	Symbols APP and ARGLU1	Name 1 amyloid beta precursor protein	Name2 arginine and glutamate rich 1	Pathway 1 Platelet degranulation ECM proteoglycans Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs) G alpha (q) signalling events G alpha (i) signalling events Lysosome Vesicle Biogenesis Formyl peptide receptors bind formyl peptides and many other ligands TAK1-dependent IKK and NF-kappa-B activation The NLRP3 inflammasome Advanced glycosylation endproduct receptor signaling Advanced glycosylation endproduct receptor signaling Deregulated CDK5 triggers multiple neurodegenerative pathways in Alzheimer's disease models Post-translational protein phosphorylation TRAF6 mediated NF-kB activation Insertion of tail-anchored proteins into the endoplasmic reticulum membrane Insertion of tail-anchored proteins into the endoplasmic reticulum membrane Purinergic signaling in leishmaniasis infection Amyloid fiber formation	Pathway 2	Drugs 1 Deferoxamine Aluminium Zinc L-methionine (R)-S-oxide Resveratrol Tromethamine Phenserine Tetrathiomolybdate CAD106 Mito-4509 Edonerpic Dimercaprol Copper Florbetaben (18F) Florbetapir (18F) Flutemetamol (18F) Gantenerumab Aducanumab Zinc acetate Aluminium phosphate Aluminum acetate Zinc chloride Zinc sulfate, unspecified form Lecanemab	Drugs 2	Diseases 1 Alzheimer's disease (AD)	Diseases 2
Novel	Symbols APP and POLD3	Name 1 amyloid beta precursor protein	Name2 DNA polymerase delta 3, accessory subunit	Pathway 1 Platelet degranulation ECM proteoglycans Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs) G alpha (q) signalling events G alpha (i) signalling events Lysosome Vesicle Biogenesis Formyl peptide receptors bind formyl peptides and many other ligands TAK1-dependent IKK and NF-kappa-B activation The NLRP3 inflammasome Advanced glycosylation endproduct receptor signaling Advanced glycosylation endproduct receptor signaling Deregulated CDK5 triggers multiple neurodegenerative pathways in Alzheimer's disease models Post-translational protein phosphorylation TRAF6 mediated NF-kB activation Insertion of tail-anchored proteins into the endoplasmic reticulum membrane Insertion of tail-anchored proteins into the endoplasmic reticulum membrane Purinergic signaling in leishmaniasis infection Amyloid fiber formation	Pathway 2 Recognition of DNA damage by PCNA-containing replication complex Polymerase switching on the C-strand of the telomere Processive synthesis on the C-strand of the telomere Telomere C-strand (Lagging Strand) Synthesis Removal of the Flap Intermediate from the C-strand Mismatch repair (MMR) directed by MSH2:MSH6 (MutSalpha) Mismatch repair (MMR) directed by MSH2:MSH3 (MutSbeta) PCNA-Dependent Long Patch Base Excision Repair Termination of translesion DNA synthesis HDR through Homologous Recombination (HRR) Gap-filling DNA repair synthesis and ligation in GG-NER Dual Incision in GG-NER Dual incision in TC-NER Gap-filling DNA repair synthesis and ligation in TC-NER Polymerase switching Removal of the Flap Intermediate Processive synthesis on the lagging strand	Drugs 1 Deferoxamine Aluminium Zinc L-methionine (R)-S-oxide Resveratrol Tromethamine Phenserine Tetrathiomolybdate CAD106 Mito-4509 Edonerpic Dimercaprol Copper Florbetaben (18F) Florbetapir (18F) Flutemetamol (18F) Gantenerumab Aducanumab Zinc acetate Aluminium phosphate Aluminum acetate Zinc chloride Zinc sulfate, unspecified form Lecanemab	Drugs 2	Diseases 1 Alzheimer's disease (AD)	Diseases 2
Novel	Symbols APP and PLIN3	Name 1 amyloid beta precursor protein	Name2 perilipin 3	Pathway 1 Platelet degranulation ECM proteoglycans Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs) G alpha (q) signalling events G alpha (i) signalling events Lysosome Vesicle Biogenesis Formyl peptide receptors bind formyl peptides and many other ligands TAK1-dependent IKK and NF-kappa-B activation The NLRP3 inflammasome Advanced glycosylation endproduct receptor signaling Advanced glycosylation endproduct receptor signaling Deregulated CDK5 triggers multiple neurodegenerative pathways in Alzheimer's disease models Post-translational protein phosphorylation TRAF6 mediated NF-kB activation Insertion of tail-anchored proteins into the endoplasmic reticulum membrane Insertion of tail-anchored proteins into the endoplasmic reticulum membrane Purinergic signaling in leishmaniasis infection Amyloid fiber formation	Pathway 2 Triglyceride catabolism Retrograde transport at the Trans-Golgi-Network Lipophagy Chaperone Mediated Autophagy Late endosomal microautophagy RHOBTB3 ATPase cycle	Drugs 1 Deferoxamine Aluminium Zinc L-methionine (R)-S-oxide Resveratrol Tromethamine Phenserine Tetrathiomolybdate CAD106 Mito-4509 Edonerpic Dimercaprol Copper Florbetaben (18F) Florbetapir (18F) Flutemetamol (18F) Gantenerumab Aducanumab Zinc acetate Aluminium phosphate Aluminum acetate Zinc chloride Zinc sulfate, unspecified form Lecanemab	Drugs 2 Idursulfase Galsulfase	Diseases 1 Alzheimer's disease (AD)	Diseases 2
Novel	Symbols APP and TAF1B	Name 1 amyloid beta precursor protein	Name2 TATA-box binding protein associated factor, RNA polymerase I subunit B	Pathway 1 Platelet degranulation ECM proteoglycans Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs) G alpha (q) signalling events G alpha (i) signalling events Lysosome Vesicle Biogenesis Formyl peptide receptors bind formyl peptides and many other ligands TAK1-dependent IKK and NF-kappa-B activation The NLRP3 inflammasome Advanced glycosylation endproduct receptor signaling Advanced glycosylation endproduct receptor signaling Deregulated CDK5 triggers multiple neurodegenerative pathways in Alzheimer's disease models Post-translational protein phosphorylation TRAF6 mediated NF-kB activation Insertion of tail-anchored proteins into the endoplasmic reticulum membrane Insertion of tail-anchored proteins into the endoplasmic reticulum membrane Purinergic signaling in leishmaniasis infection Amyloid fiber formation	Pathway 2 SIRT1 negatively regulates rRNA expression NoRC negatively regulates rRNA expression B-WICH complex positively regulates rRNA expression RNA Polymerase I Transcription Initiation RNA Polymerase I Transcription Initiation RNA Polymerase I Promoter Escape RNA Polymerase I Transcription Termination	Drugs 1 Deferoxamine Aluminium Zinc L-methionine (R)-S-oxide Resveratrol Tromethamine Phenserine Tetrathiomolybdate CAD106 Mito-4509 Edonerpic Dimercaprol Copper Florbetaben (18F) Florbetapir (18F) Flutemetamol (18F) Gantenerumab Aducanumab Zinc acetate Aluminium phosphate Aluminum acetate Zinc chloride Zinc sulfate, unspecified form Lecanemab	Drugs 2	Diseases 1 Alzheimer's disease (AD)	Diseases 2
Novel	Symbols APP and ARL4C	Name 1 amyloid beta precursor protein	Name2 ARF like GTPase 4C	Pathway 1 Platelet degranulation ECM proteoglycans Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs) G alpha (q) signalling events G alpha (i) signalling events Lysosome Vesicle Biogenesis Formyl peptide receptors bind formyl peptides and many other ligands TAK1-dependent IKK and NF-kappa-B activation The NLRP3 inflammasome Advanced glycosylation endproduct receptor signaling Advanced glycosylation endproduct receptor signaling Deregulated CDK5 triggers multiple neurodegenerative pathways in Alzheimer's disease models Post-translational protein phosphorylation TRAF6 mediated NF-kB activation Insertion of tail-anchored proteins into the endoplasmic reticulum membrane Insertion of tail-anchored proteins into the endoplasmic reticulum membrane Purinergic signaling in leishmaniasis infection Amyloid fiber formation	Pathway 2 NR1H3 & NR1H2 regulate gene expression linked to cholesterol transport and efflux	Drugs 1 Deferoxamine Aluminium Zinc L-methionine (R)-S-oxide Resveratrol Tromethamine Phenserine Tetrathiomolybdate CAD106 Mito-4509 Edonerpic Dimercaprol Copper Florbetaben (18F) Florbetapir (18F) Flutemetamol (18F) Gantenerumab Aducanumab Zinc acetate Aluminium phosphate Aluminum acetate Zinc chloride Zinc sulfate, unspecified form Lecanemab	Drugs 2	Diseases 1 Alzheimer's disease (AD)	Diseases 2
Novel	Symbols APP and ZAP70	Name 1 amyloid beta precursor protein	Name2 zeta chain of T cell receptor associated protein kinase 70	Pathway 1 Platelet degranulation ECM proteoglycans Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs) G alpha (q) signalling events G alpha (i) signalling events Lysosome Vesicle Biogenesis Formyl peptide receptors bind formyl peptides and many other ligands TAK1-dependent IKK and NF-kappa-B activation The NLRP3 inflammasome Advanced glycosylation endproduct receptor signaling Advanced glycosylation endproduct receptor signaling Deregulated CDK5 triggers multiple neurodegenerative pathways in Alzheimer's disease models Post-translational protein phosphorylation TRAF6 mediated NF-kB activation Insertion of tail-anchored proteins into the endoplasmic reticulum membrane Insertion of tail-anchored proteins into the endoplasmic reticulum membrane Purinergic signaling in leishmaniasis infection Amyloid fiber formation	Pathway 2 Translocation of ZAP-70 to Immunological synapse Generation of second messenger molecules RHOH GTPase cycle Nuclear events stimulated by ALK signaling in cancer	Drugs 1 Deferoxamine Aluminium Zinc L-methionine (R)-S-oxide Resveratrol Tromethamine Phenserine Tetrathiomolybdate CAD106 Mito-4509 Edonerpic Dimercaprol Copper Florbetaben (18F) Florbetapir (18F) Flutemetamol (18F) Gantenerumab Aducanumab Zinc acetate Aluminium phosphate Aluminum acetate Zinc chloride Zinc sulfate, unspecified form Lecanemab	Drugs 2 Staurosporine Fostamatinib	Diseases 1 Alzheimer's disease (AD)	Diseases 2 Combined immunodeficiencies (CIDs), including the following nine diseases: X-linked hyper IgM syndrome; CD40 deficiency hyper IgM syndrome; Purine nucleoside phosphorylase (PNP) deficiency; Omenn syndrome; MHC deficiency (HLA-class I); MHC deficiency (HLA-class II); Zap-70 deficiency; p56 Lck deficiency; CD8 deficiency
Novel	Symbols APP and ATAT1	Name 1 amyloid beta precursor protein	Name2 alpha tubulin acetyltransferase 1	Pathway 1 Platelet degranulation ECM proteoglycans Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs) G alpha (q) signalling events G alpha (i) signalling events Lysosome Vesicle Biogenesis Formyl peptide receptors bind formyl peptides and many other ligands TAK1-dependent IKK and NF-kappa-B activation The NLRP3 inflammasome Advanced glycosylation endproduct receptor signaling Advanced glycosylation endproduct receptor signaling Deregulated CDK5 triggers multiple neurodegenerative pathways in Alzheimer's disease models Post-translational protein phosphorylation TRAF6 mediated NF-kB activation Insertion of tail-anchored proteins into the endoplasmic reticulum membrane Insertion of tail-anchored proteins into the endoplasmic reticulum membrane Purinergic signaling in leishmaniasis infection Amyloid fiber formation	Pathway 2 Cargo trafficking to the periciliary membrane	Drugs 1 Deferoxamine Aluminium Zinc L-methionine (R)-S-oxide Resveratrol Tromethamine Phenserine Tetrathiomolybdate CAD106 Mito-4509 Edonerpic Dimercaprol Copper Florbetaben (18F) Florbetapir (18F) Flutemetamol (18F) Gantenerumab Aducanumab Zinc acetate Aluminium phosphate Aluminum acetate Zinc chloride Zinc sulfate, unspecified form Lecanemab	Drugs 2	Diseases 1 Alzheimer's disease (AD)	Diseases 2
Novel	Symbols APP and STK25	Name 1 amyloid beta precursor protein	Name2 serine/threonine kinase 25	Pathway 1 Platelet degranulation ECM proteoglycans Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs) G alpha (q) signalling events G alpha (i) signalling events Lysosome Vesicle Biogenesis Formyl peptide receptors bind formyl peptides and many other ligands TAK1-dependent IKK and NF-kappa-B activation The NLRP3 inflammasome Advanced glycosylation endproduct receptor signaling Advanced glycosylation endproduct receptor signaling Deregulated CDK5 triggers multiple neurodegenerative pathways in Alzheimer's disease models Post-translational protein phosphorylation TRAF6 mediated NF-kB activation Insertion of tail-anchored proteins into the endoplasmic reticulum membrane Insertion of tail-anchored proteins into the endoplasmic reticulum membrane Purinergic signaling in leishmaniasis infection Amyloid fiber formation	Pathway 2	Drugs 1 Deferoxamine Aluminium Zinc L-methionine (R)-S-oxide Resveratrol Tromethamine Phenserine Tetrathiomolybdate CAD106 Mito-4509 Edonerpic Dimercaprol Copper Florbetaben (18F) Florbetapir (18F) Flutemetamol (18F) Gantenerumab Aducanumab Zinc acetate Aluminium phosphate Aluminum acetate Zinc chloride Zinc sulfate, unspecified form Lecanemab	Drugs 2	Diseases 1 Alzheimer's disease (AD)	Diseases 2
Novel	Symbols APP and PTPN7	Name 1 amyloid beta precursor protein	Name2 protein tyrosine phosphatase non-receptor type 7	Pathway 1 Platelet degranulation ECM proteoglycans Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs) G alpha (q) signalling events G alpha (i) signalling events Lysosome Vesicle Biogenesis Formyl peptide receptors bind formyl peptides and many other ligands TAK1-dependent IKK and NF-kappa-B activation The NLRP3 inflammasome Advanced glycosylation endproduct receptor signaling Advanced glycosylation endproduct receptor signaling Deregulated CDK5 triggers multiple neurodegenerative pathways in Alzheimer's disease models Post-translational protein phosphorylation TRAF6 mediated NF-kB activation Insertion of tail-anchored proteins into the endoplasmic reticulum membrane Insertion of tail-anchored proteins into the endoplasmic reticulum membrane Purinergic signaling in leishmaniasis infection Amyloid fiber formation	Pathway 2 Negative regulation of MAPK pathway Interleukin-37 signaling	Drugs 1 Deferoxamine Aluminium Zinc L-methionine (R)-S-oxide Resveratrol Tromethamine Phenserine Tetrathiomolybdate CAD106 Mito-4509 Edonerpic Dimercaprol Copper Florbetaben (18F) Florbetapir (18F) Flutemetamol (18F) Gantenerumab Aducanumab Zinc acetate Aluminium phosphate Aluminum acetate Zinc chloride Zinc sulfate, unspecified form Lecanemab	Drugs 2	Diseases 1 Alzheimer's disease (AD)	Diseases 2
Novel	Symbols APP and EPB41L2	Name 1 amyloid beta precursor protein	Name2 erythrocyte membrane protein band 4.1 like 2	Pathway 1 Platelet degranulation ECM proteoglycans Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs) G alpha (q) signalling events G alpha (i) signalling events Lysosome Vesicle Biogenesis Formyl peptide receptors bind formyl peptides and many other ligands TAK1-dependent IKK and NF-kappa-B activation The NLRP3 inflammasome Advanced glycosylation endproduct receptor signaling Advanced glycosylation endproduct receptor signaling Deregulated CDK5 triggers multiple neurodegenerative pathways in Alzheimer's disease models Post-translational protein phosphorylation TRAF6 mediated NF-kB activation Insertion of tail-anchored proteins into the endoplasmic reticulum membrane Insertion of tail-anchored proteins into the endoplasmic reticulum membrane Purinergic signaling in leishmaniasis infection Amyloid fiber formation	Pathway 2 Neurexins and neuroligins	Drugs 1 Deferoxamine Aluminium Zinc L-methionine (R)-S-oxide Resveratrol Tromethamine Phenserine Tetrathiomolybdate CAD106 Mito-4509 Edonerpic Dimercaprol Copper Florbetaben (18F) Florbetapir (18F) Flutemetamol (18F) Gantenerumab Aducanumab Zinc acetate Aluminium phosphate Aluminum acetate Zinc chloride Zinc sulfate, unspecified form Lecanemab	Drugs 2	Diseases 1 Alzheimer's disease (AD)	Diseases 2
Novel	Symbols APP and LIG3	Name 1 amyloid beta precursor protein	Name2 DNA ligase 3	Pathway 1 Platelet degranulation ECM proteoglycans Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs) G alpha (q) signalling events G alpha (i) signalling events Lysosome Vesicle Biogenesis Formyl peptide receptors bind formyl peptides and many other ligands TAK1-dependent IKK and NF-kappa-B activation The NLRP3 inflammasome Advanced glycosylation endproduct receptor signaling Advanced glycosylation endproduct receptor signaling Deregulated CDK5 triggers multiple neurodegenerative pathways in Alzheimer's disease models Post-translational protein phosphorylation TRAF6 mediated NF-kB activation Insertion of tail-anchored proteins into the endoplasmic reticulum membrane Insertion of tail-anchored proteins into the endoplasmic reticulum membrane Purinergic signaling in leishmaniasis infection Amyloid fiber formation	Pathway 2 Resolution of AP sites via the single-nucleotide replacement pathway APEX1-Independent Resolution of AP Sites via the Single Nucleotide Replacement Pathway HDR through MMEJ (alt-NHEJ) Gap-filling DNA repair synthesis and ligation in GG-NER Gap-filling DNA repair synthesis and ligation in TC-NER	Drugs 1 Deferoxamine Aluminium Zinc L-methionine (R)-S-oxide Resveratrol Tromethamine Phenserine Tetrathiomolybdate CAD106 Mito-4509 Edonerpic Dimercaprol Copper Florbetaben (18F) Florbetapir (18F) Flutemetamol (18F) Gantenerumab Aducanumab Zinc acetate Aluminium phosphate Aluminum acetate Zinc chloride Zinc sulfate, unspecified form Lecanemab	Drugs 2 Bleomycin	Diseases 1 Alzheimer's disease (AD)	Diseases 2
Novel	Symbols APP and PPFIBP2	Name 1 amyloid beta precursor protein	Name2 PPFIB scaffold protein 2	Pathway 1 Platelet degranulation ECM proteoglycans Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs) G alpha (q) signalling events G alpha (i) signalling events Lysosome Vesicle Biogenesis Formyl peptide receptors bind formyl peptides and many other ligands TAK1-dependent IKK and NF-kappa-B activation The NLRP3 inflammasome Advanced glycosylation endproduct receptor signaling Advanced glycosylation endproduct receptor signaling Deregulated CDK5 triggers multiple neurodegenerative pathways in Alzheimer's disease models Post-translational protein phosphorylation TRAF6 mediated NF-kB activation Insertion of tail-anchored proteins into the endoplasmic reticulum membrane Insertion of tail-anchored proteins into the endoplasmic reticulum membrane Purinergic signaling in leishmaniasis infection Amyloid fiber formation	Pathway 2 Receptor-type tyrosine-protein phosphatases	Drugs 1 Deferoxamine Aluminium Zinc L-methionine (R)-S-oxide Resveratrol Tromethamine Phenserine Tetrathiomolybdate CAD106 Mito-4509 Edonerpic Dimercaprol Copper Florbetaben (18F) Florbetapir (18F) Flutemetamol (18F) Gantenerumab Aducanumab Zinc acetate Aluminium phosphate Aluminum acetate Zinc chloride Zinc sulfate, unspecified form Lecanemab	Drugs 2	Diseases 1 Alzheimer's disease (AD)	Diseases 2
Novel	Symbols APP and TAB2	Name 1 amyloid beta precursor protein	Name2 TGF-beta activated kinase 1 (MAP3K7) binding protein 2	Pathway 1 Platelet degranulation ECM proteoglycans Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs) G alpha (q) signalling events G alpha (i) signalling events Lysosome Vesicle Biogenesis Formyl peptide receptors bind formyl peptides and many other ligands TAK1-dependent IKK and NF-kappa-B activation The NLRP3 inflammasome Advanced glycosylation endproduct receptor signaling Advanced glycosylation endproduct receptor signaling Deregulated CDK5 triggers multiple neurodegenerative pathways in Alzheimer's disease models Post-translational protein phosphorylation TRAF6 mediated NF-kB activation Insertion of tail-anchored proteins into the endoplasmic reticulum membrane Insertion of tail-anchored proteins into the endoplasmic reticulum membrane Purinergic signaling in leishmaniasis infection Amyloid fiber formation	Pathway 2 Nuclear signaling by ERBB4 Nuclear signaling by ERBB4 NOD1/2 Signaling Pathway Downstream TCR signaling FCERI mediated NF-kB activation TAK1-dependent IKK and NF-kappa-B activation activated TAK1 mediates p38 MAPK activation JNK (c-Jun kinases) phosphorylation and activation mediated by activated human TAK1 TNFR1-induced NF-kappa-B signaling pathway CLEC7A (Dectin-1) signaling TICAM1,TRAF6-dependent induction of TAK1 complex Interleukin-1 signaling IRAK2 mediated activation of TAK1 complex TRAF6-mediated induction of TAK1 complex within TLR4 complex Alpha-protein kinase 1 signaling pathway SARS-CoV-2 activates/modulates innate and adaptive immune responses IRAK2 mediated activation of TAK1 complex upon TLR7/8 or 9 stimulation	Drugs 1 Deferoxamine Aluminium Zinc L-methionine (R)-S-oxide Resveratrol Tromethamine Phenserine Tetrathiomolybdate CAD106 Mito-4509 Edonerpic Dimercaprol Copper Florbetaben (18F) Florbetapir (18F) Flutemetamol (18F) Gantenerumab Aducanumab Zinc acetate Aluminium phosphate Aluminum acetate Zinc chloride Zinc sulfate, unspecified form Lecanemab	Drugs 2	Diseases 1 Alzheimer's disease (AD)	Diseases 2
Novel	Symbols APP and LRRC8D	Name 1 amyloid beta precursor protein	Name2 leucine rich repeat containing 8 VRAC subunit D	Pathway 1 Platelet degranulation ECM proteoglycans Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs) G alpha (q) signalling events G alpha (i) signalling events Lysosome Vesicle Biogenesis Formyl peptide receptors bind formyl peptides and many other ligands TAK1-dependent IKK and NF-kappa-B activation The NLRP3 inflammasome Advanced glycosylation endproduct receptor signaling Advanced glycosylation endproduct receptor signaling Deregulated CDK5 triggers multiple neurodegenerative pathways in Alzheimer's disease models Post-translational protein phosphorylation TRAF6 mediated NF-kB activation Insertion of tail-anchored proteins into the endoplasmic reticulum membrane Insertion of tail-anchored proteins into the endoplasmic reticulum membrane Purinergic signaling in leishmaniasis infection Amyloid fiber formation	Pathway 2 Miscellaneous transport and binding events	Drugs 1 Deferoxamine Aluminium Zinc L-methionine (R)-S-oxide Resveratrol Tromethamine Phenserine Tetrathiomolybdate CAD106 Mito-4509 Edonerpic Dimercaprol Copper Florbetaben (18F) Florbetapir (18F) Flutemetamol (18F) Gantenerumab Aducanumab Zinc acetate Aluminium phosphate Aluminum acetate Zinc chloride Zinc sulfate, unspecified form Lecanemab	Drugs 2	Diseases 1 Alzheimer's disease (AD)	Diseases 2 Agammaglobulinemias, including the following six diseases: X-linked agammaglobulinemia (Bruton's agammaglobulinemia, XLA); IgM heavy chain gene deletions; Ig-alpha defect; Autosomal recessive agammaglobulinaemia; B cell-linker protein (BLNK) deficiency; Leucine-rich repeat-containing 8

Page 12 out of 98 pages

Search Results : Cancer